US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

9.62

-0.0500-0.52%

Pre-market: 9.50-0.1200-1.25%08:27 EST

Volume:105.76K

Turnover:1.01M

Market Cap:3.22B

PE:225.61

High:9.64

Open:9.55

Low:9.50

Close:9.67

52wk High:30.36

52wk Low:8.76

Shares:335.00M

Float Shares:272.00M

Volume Ratio:0.87

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.0426

EPS(LYR):0.0933

ROE:3.14%

ROA:2.08%

PB:7.64

PE(LYR):103.15

Loading ...

Overview Company News Filings

Why Telix Pharmaceuticals (ASX:TLX) Is Up 18.0% After Upgrading 2025 Revenue Guidance and Posting Strong Q3 Sales

Simply Wall St.

Citi Remains a Buy on Telix Pharmaceuticals (TLPPF)

Telix Pharmaceuticals: Strong Q3 Performance and Strategic Positioning Reinforce Buy Rating

Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett

Citi Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Jefferies Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Telix Reports Q3 Revenue Of $206M Up 53% Year Over Year, Raises FY 2025 Guidance To $800M–$820M

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

Telix Pharmaceuticals Boosts Revenue Forecast Amid Strategic Expansions

How the SEC Subpoena and Legal Probe May Influence Telix (ASX:TLX) Investor Risk Perceptions

Simply Wall St.

Telix Pharmaceuticals Issues New Securities to Bolster Strategic Growth

Barrenjoey Markets Starts Telix Pharmaceuticals at Overweight with AU$22 Price Target

MT Newswires Live

Telix Pharmaceuticals (TLPPF) Receives a Buy from Canaccord Genuity

CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Telix Announces Record-Breaking Presence at EANM 2025

Telix Pharmaceuticals Can Overcome Setbacks in U.S. -- Market Talk

Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Bell Potter Remains a Buy on Telix Pharmaceuticals (TLPPF)

Jarden Remains a Buy on Telix Pharmaceuticals (TLPPF)

Telix Pharmaceuticals' Gozellix Expected to See Strong Sales Growth After TPT Status Grant, Jarden Research Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":9.62,"timestamp":1765314000000,"preClose":9.67,"halted":0,"volume":105755,"hourTrading":{"tag":"盘前","latestPrice":9.5,"preClose":9.62,"latestTime":"08:27 EST","volume":1433,"amount":13645.478828,"timestamp":1765373220987},"delay":0,"floatShares":272000000,"shares":335000000,"eps":0.04264,"marketStatus":"Pre-Mkt","change":-0.05,"latestTime":"12-10 08:27:38 EST","open":9.55,"high":9.64,"low":9.5,"amount":1012286.331225,"amplitude":0.014478,"askPrice":9.5,"askSize":200,"bidPrice":8.61,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.04264,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765377000000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":9.62,"preHourTrading":{"tag":"盘前","latestPrice":9.5,"preClose":9.62,"latestTime":"08:27 EST","volume":1433,"amount":13645.478828,"timestamp":1765373220987},"postHourTrading":{"tag":"盘后","latestPrice":9.62,"preClose":9.62,"latestTime":"18:29 EST","volume":426,"amount":4098.12,"timestamp":1765322976287},"volumeRatio":0.8730673726709072},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":272000000,"roa":"2.08%","roe":"3.14%","lyrEps":0.093266,"volumeRatio":0.8730673726709072,"shares":335000000,"dividePrice":0,"high":9.64,"amplitude":0.014478,"preClose":9.67,"low":9.5,"week52Low":8.76,"pbRate":"7.64","psRate":"4.85","week52High":30.36,"institutionHeld":0,"latestPrice":9.62,"committee":-0.333333,"eps":0.04264,"divideRate":0,"volume":105755,"delay":0,"ttmEps":0.04264,"open":9.55,"prevYearClose":15.4,"prevWeekClose":9.85,"prevMonthClose":9.95,"prevQuarterClose":9.57,"fiveDayClose":9.48,"twentyDayClose":10.08,"sixtyDayClose":9.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1758430800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2025-12-09","current":225.609756,"percent":0.805243,"low":113.06761,"twenty":165.751711,"median":180.226962,"eighty":296.7354,"high":383.853933,"avg":211.217075,"sd":67.010536,"marketCap":3226576055.08},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6},{"date":"2025-08-08","current":119.575098,"twenty":163.364827,"median":173.121803,"eighty":185.031841,"marketCap":3879545892.37},{"date":"2025-08-15","current":118.626089,"twenty":162.985468,"median":172.816584,"eighty":184.520886,"marketCap":3844757658.1},{"date":"2025-08-22","current":367.342977,"twenty":162.565192,"median":172.783145,"eighty":185.031841,"marketCap":3983594342.69},{"date":"2025-08-29","current":297.28853,"twenty":162.917681,"median":173.086118,"eighty":186.439488,"marketCap":3223899680.91},{"date":"2025-09-05","current":280.194275,"twenty":162.97191,"median":173.155042,"eighty":187.353158,"marketCap":3038523660.62},{"date":"2025-09-12","current":284.24913,"twenty":163.053254,"median":173.392729,"eighty":189.722035,"marketCap":3082495919.22},{"date":"2025-09-19","current":299.993591,"twenty":163.181765,"median":173.840405,"eighty":192.411646,"marketCap":3253234303.96},{"date":"2025-09-26","current":303.368871,"twenty":163.269039,"median":174.34097,"eighty":195.332201,"marketCap":3289837005.56},{"date":"2025-10-03","current":316.222238,"twenty":163.331056,"median":174.844246,"eighty":197.182743,"marketCap":3429223360.77},{"date":"2025-10-10","current":308.943311,"twenty":163.584606,"median":175.579785,"eighty":198.432664,"marketCap":3350288154.24},{"date":"2025-10-17","current":337.724829,"twenty":164.112905,"median":175.99796,"eighty":200.117317,"marketCap":3662404902.51},{"date":"2025-10-24","current":335.676999,"twenty":164.422238,"median":176.508379,"eighty":204.373856,"marketCap":3640197520.67},{"date":"2025-10-31","current":328.898919,"twenty":164.871944,"median":177.318176,"eighty":280.077091,"marketCap":3566693671.28},{"date":"2025-11-07","current":302.845362,"twenty":165.230483,"median":178.059203,"eighty":285.744085,"marketCap":3284159889.46},{"date":"2025-11-14","current":289.051675,"twenty":165.371547,"median":178.295984,"eighty":290.299055,"marketCap":3134576370.19},{"date":"2025-11-21","current":278.19044,"twenty":165.561349,"median":179.014446,"eighty":289.541689,"marketCap":3016793389.39},{"date":"2025-11-28","current":310.533522,"twenty":165.669807,"median":179.412236,"eighty":291.060611,"marketCap":3367532955.32},{"date":"2025-12-05","current":306.208941,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"marketCap":3320635708.33},{"date":"2025-12-09","current":297.535329,"twenty":165.751711,"median":180.226962,"eighty":296.7354,"marketCap":3226576055.08}],"updateTime":1765363069992},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577384597","title":"Why Telix Pharmaceuticals (ASX:TLX) Is Up 18.0% After Upgrading 2025 Revenue Guidance and Posting Strong Q3 Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2577384597","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577384597?lang=en_us&edition=fundamental","pubTime":"2025-10-22 04:24","pubTimestamp":1761078279,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals announced in the past week that it has upgraded its 2025 revenue guidance to a range of US$800 million to US$820 million, up from its prior forecast, and reported unaudited third quarter group revenue of US$206 million compared to US$135 million a year earlier.\nThis combination of stronger earnings outlook and robust quarterly revenue expansion highlights the company’s ongoing operational momentum within its sector.\nWe’ll look at how this raised revenue guidance...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/why-telix-pharmaceuticals-asxtlx-is-up-180-after-upgrading-2","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/why-telix-pharmaceuticals-asxtlx-is-up-180-after-upgrading-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX"],"gpt_icon":0},{"id":"2576004604","title":"Citi Remains a Buy on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2576004604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576004604?lang=en_us&edition=fundamental","pubTime":"2025-10-20 07:05","pubTimestamp":1760915137,"startTime":"0","endTime":"0","summary":"Citi analyst Laura Sutcliffe maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$34.00. The company’s shares closed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX","BK4139"],"gpt_icon":0},{"id":"2575739032","title":"Telix Pharmaceuticals: Strong Q3 Performance and Strategic Positioning Reinforce Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2575739032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575739032?lang=en_us&edition=fundamental","pubTime":"2025-10-15 23:05","pubTimestamp":1760540727,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tara Bancroft from TD Cowen maintained ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/telix-pharmaceuticals-strong-q3-performance-and-strategic-positioning-reinforce-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/telix-pharmaceuticals-strong-q3-performance-and-strategic-positioning-reinforce-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX"],"gpt_icon":0},{"id":"2575273562","title":"Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett","url":"https://stock-news.laohu8.com/highlight/detail?id=2575273562","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575273562?lang=en_us&edition=fundamental","pubTime":"2025-10-15 10:05","pubTimestamp":1760493907,"startTime":"0","endTime":"0","summary":"In a report released today, from Ord Minnett maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$22.60. The company’s shares...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-gets-a-buy-from-ord-minnett-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-gets-a-buy-from-ord-minnett-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX","BK4139"],"gpt_icon":0},{"id":"2575571225","title":"Citi Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2575571225","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575571225?lang=en_us&edition=fundamental","pubTime":"2025-10-15 06:35","pubTimestamp":1760481337,"startTime":"0","endTime":"0","summary":"Citi analyst Laura Sutcliffe maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$34.00. The company’s shares closed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX"],"gpt_icon":0},{"id":"2575324563","title":"Jefferies Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2575324563","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575324563?lang=en_us&edition=fundamental","pubTime":"2025-10-15 01:25","pubTimestamp":1760462708,"startTime":"0","endTime":"0","summary":"In a report released today, David Stanton from Jefferies maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$27.10. The comp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF"],"gpt_icon":0},{"id":"2575263148","title":"Telix Reports Q3 Revenue Of $206M Up 53% Year Over Year, Raises FY 2025 Guidance To $800M–$820M","url":"https://stock-news.laohu8.com/highlight/detail?id=2575263148","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575263148?lang=en_us&edition=fundamental","pubTime":"2025-10-14 14:31","pubTimestamp":1760423487,"startTime":"0","endTime":"0","summary":"Telix Reports Q3 Revenue Of $206M Up 53% Year Over Year, Raises FY 2025 Guidance To $800M–$820M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/10/48190341/telix-reports-q3-revenue-of-206m-up-53-year-over-year-raises-fy-2025-guidance-to-800m-820m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2575263303","title":"Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded","url":"https://stock-news.laohu8.com/highlight/detail?id=2575263303","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575263303?lang=en_us&edition=fundamental","pubTime":"2025-10-14 14:22","pubTimestamp":1760422920,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Oct.  14, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/14/3165890/0/en/Telix-Reports-US-206M-Revenue-FY-2025-Guidance-Upgraded.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4528","LU0949170772.SGD","LU1003077747.HKD","LU2346227817.USD","LU0661504455.SGD","BK4526","BK4233","TLX","LU0738911758.USD","LU0553294199.USD","BK4144","BK4205","LU1894683264.USD","BK4208","ASX","BK4109","BK4585","LU2637428348.USD","BK4588","BK4139","BK4141","UK","CE","DCP","CMS","LU1894683348.USD","LU2500361329.USD","BK4543","LU0545039389.USD"],"gpt_icon":0},{"id":"2575542268","title":"Telix Pharmaceuticals Boosts Revenue Forecast Amid Strategic Expansions","url":"https://stock-news.laohu8.com/highlight/detail?id=2575542268","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575542268?lang=en_us&edition=fundamental","pubTime":"2025-10-14 13:57","pubTimestamp":1760421435,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals reported a significant revenue increase of 53% year-over-year for Q...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-boosts-revenue-forecast-amid-strategic-expansions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-boosts-revenue-forecast-amid-strategic-expansions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX"],"gpt_icon":0},{"id":"2575473138","title":"How the SEC Subpoena and Legal Probe May Influence Telix (ASX:TLX) Investor Risk Perceptions","url":"https://stock-news.laohu8.com/highlight/detail?id=2575473138","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575473138?lang=en_us&edition=fundamental","pubTime":"2025-10-13 12:29","pubTimestamp":1760329797,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals disclosed that it received a subpoena from the U.S. Securities and Exchange Commission regarding its disclosures about prostate cancer therapeutic candidates, with the Rosen Law Firm investigating potential securities claims and preparing a class action on behalf of shareholders.\nThis development highlights the critical impact regulatory scrutiny and legal actions can have on investor confidence and corporate transparency in the biotech sector.\nWe’ll examine how the SEC...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-the-sec-subpoena-and-legal-probe-may-influence-telix-asx","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-the-sec-subpoena-and-legal-probe-may-influence-telix-asx","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","TLX.AU","BK7067","BK4139"],"gpt_icon":0},{"id":"2574190273","title":"Telix Pharmaceuticals Issues New Securities to Bolster Strategic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2574190273","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574190273?lang=en_us&edition=fundamental","pubTime":"2025-10-10 06:39","pubTimestamp":1760049541,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) just unveiled an announcement. Telix Pharmaceuticals Limited announced the issuance of 80,000 ordinary fully pa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-issues-new-securities-to-bolster-strategic-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-issues-new-securities-to-bolster-strategic-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2573335956","title":"Barrenjoey Markets Starts Telix Pharmaceuticals at Overweight with AU$22 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2573335956","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573335956?lang=en_us&edition=fundamental","pubTime":"2025-10-07 17:42","pubTimestamp":1759830137,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has an average rating of buy and mean price target of AU$28.44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"gpt_icon":0},{"id":"2573257356","title":"Telix Pharmaceuticals (TLPPF) Receives a Buy from Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2573257356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573257356?lang=en_us&edition=fundamental","pubTime":"2025-10-06 12:05","pubTimestamp":1759723529,"startTime":"0","endTime":"0","summary":"In a report released on October 3, Madeleine Williams from Canaccord Genuity maintained a Buy rating on Telix Pharmaceuticals, with a price target ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-receives-a-buy-from-canaccord-genuity-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-receives-a-buy-from-canaccord-genuity-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLPPF","TLX"],"gpt_icon":0},{"id":"2572950737","title":"CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2572950737","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572950737?lang=en_us&edition=fundamental","pubTime":"2025-10-03 20:07","pubTimestamp":1759493271,"startTime":"0","endTime":"0","summary":"CLSA analyst Andrew Paine maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$24.25. The company’s shares closed yes...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/clsa-reaffirms-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/clsa-reaffirms-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLSA","TLPPF","TLX"],"gpt_icon":0},{"id":"2572558372","title":"Telix Announces Record-Breaking Presence at EANM 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2572558372","media":"prnewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572558372?lang=en_us&edition=fundamental","pubTime":"2025-10-01 13:57","pubTimestamp":1759298220,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Sept. 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine  to be held in Barcelona from 4 – 8 October 2025.Dr. David N. Cade, Telix Group Chief Medical Officer, said, \"We are pleased to showcase our late-stage and next generation development programs and innovations in MedTech at EANM – the largest gathering of nuclear medicine professionals worldwide. Telix presentation highlights include the Phase 3 ProstACT Global trial of TLX591 in mCRPC[1], the IPAX-Linz and IPAX-2 therapeutic trials of TLX101 in glioma, and real-world experience with TLX250-CDx in ccRCC[2]. Telix will host a sponsored symposium on CAIX[3] and FAP[4] targeting theranostics, and abstracts will also be presented from Telix's pan-tumor programs and its Rhine Pharma subsidiary, whose mission is to expand global acces","market":"other","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-announces-record-breaking-presence-at-eanm-2025-302572028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OP.USD.HKCC","BK4588","ASX","MDR.AU","XJO.AU","TGA.AU","TGA","BK7067","TLX.AU","BK7094","BK4139","SEC.AU","BK4543","BK4526","BK4109","BK4141","XAO.AU","BK4213","BK7001","ASX.AU","BK4156","BK7039","BK4585","CE","XKO.AU","TLX"],"gpt_icon":0},{"id":"2572905308","title":"Telix Pharmaceuticals Can Overcome Setbacks in U.S. -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2572905308","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572905308?lang=en_us&edition=fundamental","pubTime":"2025-10-01 07:09","pubTimestamp":1759273740,"startTime":"0","endTime":"0","summary":"2305 GMT [Dow Jones]--Telix Pharmaceuticals's shares have fallen more than 50% from February's high on setbacks that include the rejection by the Food and Drug Administration of two promising products. Telix in late August said the FDA had identified deficiencies relating to the chemistry, manufacturing, and controls package for its Zircaix kidney cancer imaging product. Telix also plans to resubmit a new drug application for its Pixclara brain cancer imaging product. Citi thinks both can be remediated. Zircaix is probably the easier ask, given the rejection was for manufacturing, it says. \"We cannot think of a good example of a biopharma company giving up on a significant pipeline asset at this point for CMC-related reasons,\" analyst Laura Sutcliffe says. \"We expect FDA to want resolution of any problems at third party sites before resubmission.\" ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU","TLX","BK4139"],"gpt_icon":0},{"id":"2570847026","title":"Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2570847026","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570847026?lang=en_us&edition=fundamental","pubTime":"2025-09-28 22:05","pubTimestamp":1759068306,"startTime":"0","endTime":"0","summary":"In a report released today, John Hester from Bell Potter maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$23.00. The comp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX"],"gpt_icon":0},{"id":"2570905028","title":"Bell Potter Remains a Buy on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2570905028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570905028?lang=en_us&edition=fundamental","pubTime":"2025-09-26 07:35","pubTimestamp":1758843329,"startTime":"0","endTime":"0","summary":"Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$23.00. The company’s shares clos...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bell-potter-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bell-potter-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX","TLPPF"],"gpt_icon":0},{"id":"2570028182","title":"Jarden Remains a Buy on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2570028182","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570028182?lang=en_us&edition=fundamental","pubTime":"2025-09-26 07:35","pubTimestamp":1758843314,"startTime":"0","endTime":"0","summary":"In a report released on September 23, Steven Wheen from Jarden maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$28.13. Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jarden-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jarden-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF","BK4139"],"gpt_icon":0},{"id":"2570846051","title":"Telix Pharmaceuticals' Gozellix Expected to See Strong Sales Growth After TPT Status Grant, Jarden Research Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2570846051","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570846051?lang=en_us&edition=fundamental","pubTime":"2025-09-25 11:38","pubTimestamp":1758771493,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals' (ASX:TLX) Gozellix is expected to experience an \"impressive sales ramp,\" with the company's prostate cancer diagnostic products continuing to gain market share, Jarden Research ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":70,"code":"91000000","status":"200"}]}}